Latest SEC Filings

Canterbury Park Holding CorpCanterbury Park Reports $16.2M Revenue in Q2 2026, Focuses on Real Estate Development

STEELE BANCORP INCSteele Bancorp Reports 188.8% Increase in Net Income for Q2 2026

Leapfrog Acquisition CorpLeapfrog Acquisition Corporation Reports Net Income of $1.1M for Quarter Ending June 30, 2026

Cannaisseur Group Inc.Cannaisseur Group Reports $0 Revenue and $95,063 Net Loss in Q2 2026

BV Financial, Inc.BV Financial Reports Q2 2026 Results with $3.5 Million Net Income

JUNIATA VALLEY FINANCIAL CORPJuniata Valley Financial Corp. Reports 32% Net Income Growth in Q2 2026

Universal TokenUniversal Token Reports No Revenue for Q2 2026, Operating Expenses Decrease Significantly

TABLE TRAC INCTable Trac Reports 81.6% Revenue Growth to $4.24 Million in Q2 2026

Invech Holdings, Inc.Invech Holdings Reports No Sales Revenue and Increased Losses in Latest 10-Q Filing

CareView Communications IncCareView Communications Reports 20% Revenue Growth to $2.85 Million in Q2 2026

BETA Technologies, Inc.BETA Technologies Reports 146% Revenue Growth to $14.7 Million in Q2 2026

Monopar TherapeuticsMonopar Therapeutics Reports Increased Net Losses and Rising R&D Expenses in Q2 2026

Neonode Inc.Neonode Reports 20.4% Revenue Decline in Q2 2026, Operating Loss Increases

NUCOR CORPNucor Corporation Reports 23% Revenue Growth to $10.4 Billion in Q2 2026

SPRUCE BIOSCIENCES, INC.Spruce Biosciences Reports $28.5 Million Net Loss in First Half of 2026

Cardiff Lexington CorpCardiff Lexington Corporation Reports Significant Financial Decline in Q2 and First Half of 2026

DYADIC INTERNATIONAL INCDyadic International Reports Q2 2026 Revenue Decline and Increased Net Loss

Aprea Therapeutics, Inc.Aprea Therapeutics Reports Financial Developments and Clinical Progress for Quarter Ending June 30, 2026

QHSLab, Inc.QHSLab Reports 40% Revenue Growth in Q2 2026 Despite Net Loss

FLYEXCLUSIVE INC.flyExclusive Reports 21.7% Revenue Growth to $111.1 Million in Q2 2026

Avalyn Pharma Inc.Avalyn Pharma Reports $28.9 Million Net Loss in Q2 2026, Driven by Increased R&D Expenses

B&G Foods, Inc.B&G Foods Reports Decline in Sales and Net Loss for Second Quarter of Fiscal 2026

Century Therapeutics, Inc.Century Therapeutics Reports $34.6 Million Net Loss in Q2 2026

Guerrilla RF, Inc.Guerrilla RF Reports 49% Revenue Growth to $8.0 Million in Q2 Fiscal 2026

CNS Pharmaceuticals, Inc.CNS Pharmaceuticals Reports Increased Net Loss and Improved Cash Position in Latest 10-Q Filing